

Version: 2.0 Revision Date: 05/12/2015 Page: 1 of 9

#### 1. PRODUCT AND COMPANY IDENTIFICATION

**Product Name** Matchcrete Clear - Part A

Recommended use Part of decorative concrete repair system

Company Roadware Incorporated Address 381 Bridgepoint Way

South Saint Paul, MN 55075

Phone 651-457-6122


**Emergency Telephone Numbers** Chem-Tel: 800-255-3924

Restrictions on use For professional or industrial use only

#### 2. HAZARDS IDENTIFICATION

### **GHS Classification**

Flammable liquids	4
Acute toxicity	4
Skin irritation	2
Eye irritation	2A
Respiratory sensitizer	1
Skin sensitizer	1
Specific organ toxicity – single exposure	3
Specific organ toxicity – repeated exposure	2



### **Hazard Statements**

H227	Combustible liquid.
H332	Harmful if inhaled.
H315	Causes skin irritation.
H319	Causes serious eye irritation.

May cause drowsiness or dizziness. H336

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

May cause an allergic skin reaction. H317 May cause respiratory irritation. H335

May cause damage to organs (respiratory system) through prolonged or repeated exposure H373

(inhalation).

## Precautionary statements:

Wear protective gloves/eye protection/face protection.

Wash skin thoroughly after handling.

Keep away from flames and hot surfaces. No smoking.

Avoid breathing dust, fume, gas, vapors or spray. Use outdoors or only in well ventilated area. In case of inadequate ventilation wear respiratory protection.



Version: 2.0 Revision Date: 05/12/2015 Page: 2 of 9

## Response statements:

If on skin: Rinse skin with plenty water.

If skin irritation or rash occurs: Get medical advice/attention. Take off contaminated clothing and wash before reuse.

Contaminated work clothing must not be allowed out of the workplace.

If inhaled: If breathing is difficult, remove person to fresh air and keep at rest in a comfortable position for breathing. Call a poison center or doctor/physician if you feel unwell. If experiencing respiratory symptoms: Contact a poison center or doctor/physician.

If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: get medical advice/attention.

In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for extinction.

Storage: Store in a well-ventilated place. Keep cool. Keep container tightly closed. Store locked up.

Disposal: Dispose of contents and container in accordance with existing federal, state and local environmental control laws.

## Section 3. Composition / Information on Ingredients

This product is a mixture.

## **Hazardous Components**

CAS Number	Chemical Name	Concentration
28182-81-2	Homopolymer of Hexamethylene Diisocyanate	60-80%
53880-05-0	Isophorone Diisocyanate Homopolymer	10-20%
64742-94-5	Solvent naphtha, heavy	1-15%
98-06-6	Butylbenzene, tert-	0-7%
527-53-7	Benzene, 1,2,3,5-tertramethyl-	0-3%
105-05-5	1,4-Diethylbenzene	0-3%
91-20-3	Naphthalene	0-2%
488-23-3	1,2,3,4-Tetramethylbenzene	0-2%
526-73-8	Benzene, 1,2,5-trimethyl-	0-2%
1074-43-8	3-Propyltolulene	0-2%

Specific chemical identities and exact percentages may have been withheld as a trade secret or CBI in compliance with 29 CFR 1910.1200 (i).

### 4. First Aid Measures

General Advice	Take proper precautions to ensure your own health and safety before attempting rescue or administering first aid. Wear protective clothing and gloves. See section 8 for recommendations. Remove contaminated clothing. Move to a well ventilated area or outdoors.
Skin Contact	This material contains components that are skin sensitizers. After contact with skin, wash immediately with plenty of soap and water. Get medical attention if irritation or rash develops. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Inhalation	If inhaled, move affected persons to fresh air. If not breathing, give artificial respiration. Get medical attention immediately. Treatment is symptomatic for primary irritation or bronchospasm. If breathing is labored, qualified personnel should administer oxygen.
Ingestion	If swallowed, get medical attention immediately. Wash out mouth with water. DO NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Most important symptoms and effects (acute and delayed)	Most important symptoms and effects are described in section 2 and/or section 11.  Isocyanate vapors or mist at levels above the TLV or PEL can irritate the respiratory tract (nose, throat, lungs). Respiratory sensitization may result in allergic or asthmatic like symptoms including difficulty breathing, coughing, shortness of breath and wheezing. These symptoms may be delayed several hours after exposure. These effects are usually reversible. Persons with a preexisting bronchial hyper-reactivity to Isocyanates may respond to levels below the TLV or



Version: 2.0 Revision Date: 05/12/2015 Page: 3 of 9

	PEL with similar asthmatic like symptoms. Exposure to levels well above the exposure limits can result in bronchial spasm, bronchitis, pulmonary edema and may include flu-like symptoms. Exposure to high vapor concentrations well above the exposure limits of heavy aromatic solvents can cause central nervous system depression, dizziness, light headedness, headache, nausea, and loss of coordination.
Notes to Physician	Symptomatic and supportive therapy as needed. Following severe exposure medical follow-up should be monitored for at least 48 hours. Specific antidotes or neutralizers to isocyanates do not exist. Treat symptomatically. Potential for chemical or hypersensitivity pneumonitis, treat appropriately. May cause temporary corneal injury, stain for evidence to injury. If cornea is burned, install antibiotic/steroid preparation as needed.

5. Firefighting Measures

or r mongriting mode area	
Suitable Extinguishing Media	Dry chemical, Carbon Dioxide (CO2), alcohol resistant foam, water fog.
Not Suitable Extinguishing Media	Avoid high volume water jet, may spread fire.
Special exposure hazards	In a fire or if heated, a pressure increase will occur and the container may burst. Produces oxides of carbon and nitrogen as well as isocyanates. Combustion products may be toxic and/or irritating. Avoid smoke.
Special protective equipment for fire-fighters	Fire fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. PVC boots, gloves, safety helmet and protective clothing should be worn.
Special remarks on explosion hazards	Due to reaction with water producing CO2 gas, a hazardous build-up of pressure could result if contaminated containers are re-sealed. Containers may burst if overheated.

## 6. Accidental Release Measures

Personal protection	Immediately contact emergency personnel. Isolate the area. Keep upwind avoiding inhalation of vapors. Clean up should only be performed by trained personnel. People dealing with major spillages should wear full protective clothing including respiratory protection. Use suitable protective equipment (see section 8).
Environmental precautions	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.
Methods for cleaning up	Contain and adsorb large spillages onto an inert, non-flammable adsorbent carrier (such as earth, vermiculite or sand). Shovel into open-top drums or plastic bags for further decontamination if necessary. Do not tightly seal containers as pressure from generated gases may result in container rupture. Wash the spillage area clean with liquid decontaminant. Test atmosphere for MDI. Neutralize small spillages with decontaminant. Remove and properly dispose of residues (see section 13). Notify applicable government authorities if release is reportable. The CERCLA for the naphthalene as found in this mixture is approximately 3000 lbs. and 15,000 lbs. for isocyanate.

7. Handling and Storage

Handling	Put on appropriate personal protective equipment (see section 8). Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Persons with a history of skin sensitization problems or asthma, allergies or
	chronic or recurrent respiratory disease should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not breathe vapor or mist. Do no ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Keep in the original container or an approved alternative made from a compatible material. Keep tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.



Version: 2.0 Revision Date: 05/12/2015 Page: 4 of 9

Storage	Keep container in a cool, well-ventilated area. Keep container tightly closed. Keep away from moisture. Due to reaction with water producing CO2 gas, a hazardous
	build-up of pressure may result if contaminated containers are resealed. Do not reseal
	contaminated containers. Uncontaminated containers, free of moisture, may be resealed only after placing under a nitrogen blanket. Do not store in containers made
	of copper, copper alloys or galvanized surfaces.
Safe storage temperature	60 - 100° F

## 8. Exposure Controls / Personal Protection

**Exposure Limits** 

CAS Number	Component	Value type	Limit / Standard	Notes	Source
28182-81-2	Homopolymer of Hexamethylene Diisocyanate	TWA	0.005 ppm		ACGIH
53880-05-0	Isophorone Diisocyanate Homopolymer	TWA	0.005 ppm		ACGIH
64742-94-5	Solvent naphtha, heavy	TWA	500 ppm 2000 mg/m3		OSHA Z1
64742-94-5	Solvent naphtha, heavy	TWA	200 mg/m3	Total hydrocarbons	ACGIH
64742-94-5	Solvent naphtha, heavy	TWA	400 ppm 1600 mg/m3		OSHA P0
91-20-3	Naphthalene	TWA	10 ppm		ACGIH
91-20-3	Naphthalene	STEL	15 ppm		ACGIH
91-20-3	Naphthalene	TWA	10 ppm 50 mg/m3		NIOSH REL
91-20-3	Naphthalene	ST	15 ppm 75 mg/m3		NIOSH REL
91-20-3	Naphthalene	TWA	10 ppm 50 mg/m3		OSHA Z1
91-20-3	Naphthalene	TWA	10 ppm 50 mg/m3		OSHA P0
91-20-3	Naphthalene	STEL	15 ppm 75 mg/m3		OSHA P0
526-73-8	Benzene, 1,2,5-trimethyl-	TWA	25 ppm 125 mg/m3		NIOSH REL

Preventive Measures	Conditions of use, adequacy of engineering or other control measures and actual exposures will dictate the need for specific protective devices at your workplace. Medical supervision of all employees who handle or come in contact with respiratory sensitizers is recommended. Persons with respiratory problems including asthmatic-type conditions, chronic bronchitis, or other chronic respiratory diseases or recurrent skin eczema or skin allergies should be evaluated for their suitability of working with this product. Once a person is diagnosed as sensitized, no further exposure to the material that caused the sensitization should be permitted.
Engineering Controls	Use local exhaust ventilation to maintain airborne concentrations below the TLV. Suitable respiratory equipment should be used in cases of insufficient ventilation or where operational procedures demand it. For guidance on engineering control measures refer to publications such as the ACGIH current edition of 'Industrial Ventilation, a manual of Recommended Practice.'
Personal Protection Eyes Skin	Chemical safety goggles. If there is a potential for splashing, use a full face shield.  Protective clothing should be selected and used in accordance with 'Guidelines for the



Version: 2.0 Revision Date: 05/12/2015 Page: 5 of 9

Selection of Chemical Protective Clothing' published by ACGIH.

Respiratory When the product is sprayed or heated without adequate ventilation, an approved

MSHA/NIOSH positive pressure, supplied-air respirator may be required. Air purifying respirators equipped with organic vapor cartridges and a HEPA (P100) particulate filter may be used under certain conditions when a cartridge change-out schedule has been developed

in accordance with OSHA respiratory protection standard (29 CFR 1910.134).

Hands Chemical-resistant, impervious gloves complying with an approved standard should be worn

at all times when handling chemical products. Nitrile rubber has shown good results. Thin latex or vinyl disposable gloves should be avoided. Consult with producers of protective

gloves for suitability.

Other Protection Consult your supervisor or S.O.P. for special handling instructions.

9. Physical and Chemical Properties

3. I Hysical and Offermean Top	001.100
General Information	
Physical state	Liquid
Color	Clear brown
Odor	Hydrocarbon like
Odor Threshold	No data available
рН	No data available
Boiling point	> 200 °C
Melting point	Not available
Flash point	> 63 °C (145 °F) PMCC
Flammability	Combustible
Explosive properties	Non-explosive in the presence of the following materials or conditions: Open flames, sparks and static discharge and shocks and mechanical impacts.
Auto-ignition temperature	> 449 °C
Evaporation Rate	Very slow
Solubility (n-octanol/water)	No data available
Partition coefficient	No data available
Decomposition temperature	No data available
Relative density	1.1
Vapor pressure	No data available
Vapor density	No data available
Viscosity	450 cps
VOC content	No data available

10. Stability and Reactivity

Stability and reactivity	Stable at room temperature. Reaction with water (moisture) produces CO2 gas. Exothermic reaction with materials containing active hydrogen groups. This product is insoluble with water and moisture laden air. It will react with water slowly at the interface creating a solid water-insoluble layer of polyurea and liberating carbon dioxide gas.
Conditions of instability	Avoid high temperatures.
Incompatibility with various substances	Water, alcohols, amines, bases and acids.
Hazardous polymerization	Polymerization may occur with incompatible reactants, especially strong bases (alkalies, tertiary amines, metal salts), water, or temperatures over 160°C (320°F).
Hazardous decomposition products	Combustion products may include: carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), hydrocarbons and other undetermined components.

#### 11. Toxicological Information

No product specific toxicological information is available. Data obtained on components are summarized below.

Component	nponent
-----------	---------



# Safety Data Sheet Matchcrete Clear – Part A Version: 2.0

Version: 2.0 Revision Date: 05/12/2015 Page: 6 of 9

Homopolymer of Hexamethylene Diisocyanate (HDI)							
Isophorone Diisocyanate Homopolymer (IPDI)							
Likely routes of exposure: Skin contact, Inhalation, eye contact  Acute Toxicity  Inhalation: At room temperature vapors are expected to be minimal due to the low vapor pressure (ability to evaporate) of both HDI and IPDI. Isocyanate vapors or mists above the TL or PEL can result in irritation of the respiratory tract (nose, throat, lungs). Symptoms include runny nose, shortness of breath, coughing or wheezing, chest tightness or difficulty breathing HDI  Oral: LD50: rat, > 5000 mg/kg  IPDI Oral: LD50: rat, > 10.39 mg/l 4hrs. Dermal: LD50: rat, > 5000 mg/kg  Repeated exposure may cause allergic type reactions including rash, itching, irritation and redness. Skin contact is unlikely to result in absorption of significant amounts. Cured material can be difficult to remove.  Eye Damage Eye Irritation Respiratory or Skin sensitization Skin sensitization  Respiratory or skin sensitization  Respiratory Sensitizer. Concentrations above the TLV or PEL can cause allergic symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Carcinogenicity  Nor defects observed  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Nor data available  Nor data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 28 days  IPDI: NOAEL: 2.9, inhalation, fat, 6hrs/day 5 days/week 28 days  IPDI: NOAEL: 2.9, inhalation, fat, 6hrs/day 5 days/week 28 days  IPDI: NOAEL: 2.9, inhalati							
Inhalation: At room temperature vapors are expected to be minimal due to the low vapor pressure (ability to evaporate) of both HDI and IPDI. socyanate vapors or mists above the TL or PEL can result in Irritation of the respiratory tract (nose, throat, lungs). Symptoms include runny nose, shortness of breath, coughing or wheezing, chest tightness or difficulty breathing HDI Oral: LD50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 30 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat,	53880-05-0	Isophorone Diisocyanate Homopolymer (IPDI)					
Inhalation: At room temperature vapors are expected to be minimal due to the low vapor pressure (ability to evaporate) of both HDI and IPDI. socyanate vapors or mists above the TL or PEL can result in Irritation of the respiratory tract (nose, throat, lungs). Symptoms include runny nose, shortness of breath, coughing or wheezing, chest tightness or difficulty breathing HDI Oral: LD50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 30 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l Ahrs. Dermal: LD50: rat,							
pressure (ability to evaporate) of both HDI and IPDI. Isocyanate vapors or mists above the TL or PEL can result in irritation of the respiratory tract (nose, throat, lungs). Symptoms include runny nose, shortness of breath, coughing or wheezing, chest tightness or difficulty breathing HDI Oral: LD50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 2.39 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 6 mg/l 4hrs. Dermal:							
or PEL can result in irritation of the respiratory tract (nose, throat, lungs). Symptoms include runny nose, shortness of breath, coughing or wheezing, chest tightness or difficulty breathing HDI Oral: LD50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 5000 mg/kg Inhalation: LD50: rat, > 51000 mg/kg Inhalation: LD50: rat, > 5000 mg/kg Inhalation: LD50: rat, > 51000 mg/k	Acute Toxicity						
runny nose, shortness of breath, coughing or wheezing, chest tightness or difficulty breathing HDI Oral: LD50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 0.39 mg/l 4hrs. Dermal: LD50: rat, > 0.000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 0.000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 0.000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 0.000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 5 mg/							
HDI Oral: LD50: rat, > 5000 mg/kg Inhalation: LC50: rat, > 0.39 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg Skin Corrosion Skin Corrosion Repeated exposure may cause allergic type reactions including rash, liching, irritation and redness. Skin contact is unlikely to result in absorption of significant amounts. Cured material can be difficult to remove.  Eye Damage Eye Irritation Respiratory or Skin sensitization Skin sensitization Skin sensitization Respiratory or Skin sensitization S							
Oral: LD50: rat, > 000 mg/kg Inhalation: LC50: rat, > 0.39 mg/l 4hrs. Dermal: LD50: rat, > 0.30 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: LD50: rat, > 0.30 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal: Dermal: LD50: rat, > 0.30 mg/kg Inhalation: LC50: rat, > 5 mg/l 4hrs. Dermal:		runny nose, shortness of breath, coughing or w					
Inhalation: LC50: rat, > 0.39 mg/l 4hrs. Dermal: LD50: rat, > 2000 mg/kg  Skin Corrosion Skin Irritation  Repeated exposure may cause allergic type reactions including rash, itching, irritation and redness. Skin contact is unlikely to result in absorption of significant amounts. Cured material can be difficult to remove.  Eye Damage Eye Irritation  Respiratory or Skin sensitization  Skin sensitization  Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No data available  No data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  No data available  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Irrhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness, and loss of coordinatio Oral: Minimally toxic. Exposure to le		HDI	IPDI				
Dermal: LD50: rat, > 2000 mg/kg			Oral: LD50: rat, > 14000 mg/kg				
Skin Corrosion Skin Irritation Repeated exposure may cause allergic type reactions including rash, itching, irritation and redness. Skin contact is unlikely to result in absorption of significant amounts. Cured material can be difficult to remove.  Eye Damage Eye Irritation Respiratory or Respiratory or Skin sensitization Skin sensitization Skin sensitization  Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated ski contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Target Organ Systematic Toxicity —  Repeated Exposure  Target Organ Systematic Toxicity —  Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days  Repeated Exposure  Acute Toxicity  Acute Toxicity  Repoductive toxicity  Acute Toxicity Acute		Inhalation: LC50: rat, > 0.39 mg/l 4hrs.	Inhalation: LC50: rat, > 5 mg/l 4hrs.				
Eye Damage Eye Irritation  Eye Damage Eye Irritation  Respiratory or Skin sensitization  Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity  Reproductive toxicity  Reproductive toxicity  No effects observed  Target Organ Systematic Toxicity— Repeated Exposure  Target Organ Systematic Toxicity— Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizzin							
Eye Damage Eye Irritation Respiratory or Skin sensitization Skin sensitization Respiratory or Skin sensitization Respiratory or Skin sensitization Respiratory or Skin sensitization Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates. Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity Reproductive toxicity No effects observed  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Revolution Toxicity  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Skin Corrosion	Repeated exposure may cause allergic type rea	actions including rash, itching, irritation and				
Eye Damage Eye Irritation Respiratory or Skin sensitization Sens and possible role in respiratory isocyanate sensitization Irritation: Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in la	Skin Irritation	redness. Skin contact is unlikely to result in abs	orption of significant amounts. Cured material				
Eye Irritation Respiratory or Respiratory or Skin sensitization  Respiratory or Skin sensitization  Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexiting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No effects observed  No effects observed  No data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days  Respiration Toxicity  Acute Toxicity  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.		can be difficult to remove.					
Eye Irritation Respiratory or Respiratory or Skin sensitization  Respiratory or Skin sensitization  Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexiting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No effects observed  No effects observed  No data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days  Respiration Toxicity  Acute Toxicity  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Eye Damage	Causes eye irritation, swelling and redness. Ma	y cause temporary corneal injury. Prolonged				
Respiratory or Skin sensitization  Respiratory Sensitizer: Concentrations above the TLV or PEL can cause allergic symptoms including asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity  Reproductive toxicity  Reproductive toxicity  Reproductive toxicity  Target Organ Systematic Toxicity – No data available  Tritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
Skin sensitization  lincluding asthma attack, bronchitis, bronchial spasms, and pulmonary edema. These symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No effects observed  No data available  No data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.			ne TLV or PEL can cause allergic symptoms				
symptoms can be delayed for several hours after exposure. These effects are usually reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to be associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Mutagenicity  Reproductive toxicity  Single Exposure  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
reversible although decreased lung function and asthmatic reactions have been associated with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Mutagenicity  Reproductive toxicity  No effects observed  No data available  Systematic Toxicity – Single Exposure  Target Organ  Systematic Toxicity – Repeated Exposure  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
with overexposure to isocyanates. Persons with a preexisting sensitivity to isocyanates may react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Other Cell Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
react to levels below the TLV or PEL. Use of this product in a manner consistent with the recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skir contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No effects observed  No data available  Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Tiritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
recommended application procedures and current exposure guidelines is expected to protect against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No effects observed  No data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
against these effects reported for isocyanates.  Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Systematic Toxicity – Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in centra nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
Skin Sensitization: Some animal research studies have associated prolonged or repeated skin contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Mutagenicity  Reproductive toxicity  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Holis No data available  Systematic Toxicity – Structure observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.			5				
contact with skin sensitization and a possible role in respiratory isocyanate sensitization.  Carcinogenicity  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  Mutagenicity  Reproductive toxicity  Reproductive toxicity  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol.  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.			es have associated prolonged or repeated skin				
Carcinogenicity  Germ Cell Mutagenicity  Reproductive toxicity  Target Organ Systematic Toxicity - Single Exposure  Target Organ Systematic Toxicity - Repeated Exposure  Target Organ Systematic Toxicity - Repeated Exposure  Target Organ Systematic Toxicity - Repeated Exposure  Aspiration Toxicity  Aspiration Toxicity  Acute Toxicity  Acute Toxicity  Not considered a human carcinogen as defined by the IARC, NTP, OSHA.  No effects observed  No effects observed  No effects observed  No data available  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol.  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
No effects observed	Carcinogenicity						
Mutagenicity Reproductive toxicity Reproductive toxicity  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
Reproductive toxicity  Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness, and incomplete toxicity of the coordination							
Target Organ Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Caposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordination Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.		No effects observed					
Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	reproductive toxicity	THO CITEGO OBSCIVED					
Systematic Toxicity – Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Target Organ	No data available					
Single Exposure  Target Organ Systematic Toxicity – Repeated Exposure  Aspiration Toxicity  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Acute Toxicity  Single Exposure  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days  IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  No data available  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.		140 data available					
Target Organ Systematic Toxicity – Repeated Exposure Repeated Exposure Aspiration Toxicity  Solvent naphtha, heavy Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been observed in laboratory animals repeatedly exposed to excessive levels of isocyanate aerosol. HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  No data available  Solvent naphtha, heavy Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	,						
Systematic Toxicity – Repeated Exposure  Repeated Exposure  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  Aspiration Toxicity  No data available  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.		Irritation to lungs and nasal cavity. Tissue injury in the upper respiratory tract has been					
Repeated Exposure  HDI: NOAEL: 0.41, inhalation, rat, 6hrs/day 5 days/week, 28 days IPDI: NOAEL: 2.9, inhalation, rat, 6hrs/day 5 days/week 13 weeks  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordination Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
Aspiration Toxicity  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.							
Aspiration Toxicity  No data available  64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Repeated Exposure						
64742-94-5  Solvent naphtha, heavy  Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Aspiration Toxicity	···					
Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Aspiration Toxicity	NO data available					
Likely routes of exposure: Skin contact, inhalation, eye contact  Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	64742.04.5	Colvent nonhtha heavy					
Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordination Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	04742-94-5	Solvent napritria, neavy					
Acute Toxicity  Inhalation: Minimally toxic. Exposure to levels exceeding the TLV or PEL may result in central nervous system depression. Symptoms include drowsiness, dizziness and loss of coordination Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.		Likely routes of exposure: Skip contact inhalati	on ava contact				
nervous system depression. Symptoms include drowsiness, dizziness and loss of coordinatio <i>Oral</i> : Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Acute Texicity						
Oral: Minimally toxic. May cause gastro-intestinal pain, coughing, headache, dizziness, diarrhea, nausea, vomiting and unconsciousness.	Acute Toxicity	·	,				
diarrhea, nausea, vomiting and unconsciousness.							
Dames I. Minimally, taxia. May page almost a district to the line and decrease?							
		Dermal: Minimally toxic. May cause dryness leading to itching and dermatitis.					
Toxicity estimates:			-0 / A lara				
Inhalation: LC50, rat, male/female > 4600 mg/m3 / 4 hrs							
Oral: LD50, rat, male/female: > 5000 mg/kg							
Dermal: LD50, rabbit, > 3000 mg/kg	011-0		been Net englished a 12				
Skin Corrosion Causes skin irritation, redness, dryness or roughness. Not considered a skin corrosive		Causes skin irritation, redness, dryness or roug	nness. Not considered a skin corrosive				
Skin Irritation							



Version: 2.0 Revision Date: 05/12/2015 Page: 7 of 9

Eye Damage	Irritating to eyes. Not expected to cause serious eye damage
Eye Irritation	Niet som setellte ha selike som ittere
Respiratory or	Not expected to be a skin sensitizer.
Skin sensitization	Did not cause sensitization in laboratory animals.
Carcinogenicity Germ Cell	Not considered a human carcinogen as defined by the IARC, NTP, OSHA.
	Negative
Mutagenicity Reproductive toxicity	No reproductive effects. No teratogenic effects on fetal development.
Target Organ	Inhalation: Central nervous system, May cause drowsiness and/or dizziness. Possible narcotic
Systematic Toxicity –	effects including nausea and vomiting when over exposed to levels beyond the TLV or PEL.
Single Exposure	
Target Organ	Not expected to cause organ damage from prolonged or repeated exposure. Based on the
Systematic Toxicity – Repeated Exposure	physical-chemical properties of this material when compared with test data from similar compounds
Aspiration Toxicity	Aspiration into the lungs if swallowed or when vomiting may cause chemical pneumonitis which can be fatal.
	can be latal.
98-06-6	Butylbenzene, tert-
527-53-7	Benzene, 1,2,3,5-tertramethyl-
91-20-3	Naphthalene
105-05-5	1,4-Diethylbenzene
488-23-3	1,2,3,4-Tetramethylbenzene
526-73-8	Benzene, 1,2,5-trimethyl-
1074-43-8	3-Propyltolulene
95-63-6	1,2,4-trimethlybenzene
496-11-7	1H-Indene, 2,3-dihydro-
25340-17-4	Benzene, diethyl-
	Likely routes of exposure: Skin contact, inhalation, eye contact
Acute Toxicity	No data available
Skin Corrosion	No data available
Skin Irritation	
Eye Damage	No data available
Eye Irritation	
Respiratory or	No data available
Skin sensitization	
Carcinogenicity	Naphthalene
	IARC 2B - 2B, possible human carcinogen.
	ACGIH – A3 Confirmed animal carcinogen. Relevance to humans is unknown.
	NTP – Reasonably anticipated to be a human carcinogen.
Germ Cell	No data available
Mutagenicity	
Reproductive toxicity	No data available
Target Organ	No data available
Systematic Toxicity –	
Single Exposure	
Target Organ	No data available
Systematic Toxicity –	
Repeated Exposure	
Aspiration Toxicity	No data available

## 12. Ecological Information

No product specific ecological information is available. Data obtained on components are summarized below.



Version: 2.0 Revision Date: 05/12/2015 Page: 8 of 9

Very toxic to aquatic life with long lasting effects. Avoid dispersal of spilled material and runoff from contact with soil, waterways, drains and sewers. Improper or unprofessional handling or disposal can create an environmental hazard.

Component				
28182-81-2	Homopolymer of Hexamethylene Diisocyanate (HDI)			
53880-05-0	Isophorone Diisocyanate Homopolymer (IPDI)			
Persistence and degradability	In aquatic environments these components react with water to create carbon			
	dioxide gas and insoluble polyureas. In atmospheric environments material has a			
	short tropospheric half-life. Not degradable. Not considered persistent.			
	(HDI) Aerobic, 2%, 28 days: not readily biodegradable			
	(IPDI) Aerobic, 0%, 28 days: not readily biodegradable			
Mobility	No data available			
Bioaccumulation	Not considered to be bio-accumulative			
	9.6 BCF (HDI)			
	bioaccumulation not expected (IPDI)			
Ecotoxicity effects	No product specific data available			
Aquatic toxicity	(HDI): LC50: > 100 mg/l (zebra fish/Brachydanio rerio), 96 hours			
	EC50: > 100 mg/l (water flea/Daphnia magna), 48 hours			
	ErC50: > 199 mg/l (scenedesmus subspicatus), 72 hours			
	EC50: > 1000 mg/l (activated sludge microorganisms), 3 hours			
	(IPDI): LC50: > 1.51 mg/l (carp/Cyprinus carpio), 96 hours			
	EC50: > 3.36 mg/l (water flea/Daphnia magna), 48 hours			
	ErC50: > 3.1 mg/l (scenedesmus subspicatus), 72 hours			
	EC50: > 10000 mg/l (activated sludge microorganisms), 3 hours			
64742-94-5	Solvent naphtha, heavy			
Persistence and degradability	In aquatic environments this component does not readily biodegrade. Readily			
reisisterice and degradability	biodegrades into the atmosphere, soils.			
	Aerobic, 30%, 28 dyas: Not readily biodegradable			
Mobility	No data available			
Bioaccumulation	Not likely to bioaccumulate			
Dioaccamalation	Partition coefficient: n-octanol/water: log Pow: 3.2 - 4.5			
Ecotoxicity effects	No data available			
Aquatic toxicity	LC50: > 2 mg/l (rainbow trout/Oncorhynchus mykiss) 96 hours			
, iqualo tomolty	EC50: > 1.4 mg/l (water flea/Daphnia magna), 48 hours			
	EC50: > 1-3 mg/l (Pseudokirchneriella subcapitata), 72 hours			

## 13. Disposal Considerations

Waste disposal	The generation of waste should be avoided or minimized wherever possible. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Disposal of this product, solutions and any by-product should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Contaminated containers should be emptied. Do not reuse containers. Do not burn or use a cutting torch on empty containers.
U.S. EPA RCRA	EPA resource recovery act (RCRA) composite list of hazardous wastes and Appendix VIII Hazardous constituents (40 CFR 261): Under RCRA, it is the responsibility of the person who generates a solid waste to determine if that waste is a hazardous waste as defined by 40 CFR 261.2.

## 14. Transportation Information

Regulatory	UN Number	Proper Shipping	Class	PG*	Label	Additional information
Information		Name				
DOT Classification	Not regulated					Not regulated for non-bulk



Version: 2.0 Revision Date: 05/12/2015 Page: 9 of 9

				packaging
TDG Classification	Not regulated			
IMDG Class	Not regulated			
IATA-DGR Class	Not regulated			

## 15. Regulatory Information

United States Federal Regulations	
U.S. Toxic Substances Control Act (TSCA 8b)	All components are listed or exempted.
CERCLA – reportable quantity, calculated	5,000 lbs. (approximately 660 gallons), 91-20-3,
	Naphthalene
SARA 304 Extremely Hazardous Substances RQ	Does not contain any components subject to 304 EHS RQ
SARA 311 / 312	Acute health hazard
	Chronic health hazard
EPA Community Right To Know Act (EPCRA) SARA Title	CAS 91-20-3, Naphthalene
III Section 313, components requiring notification.	
Clean Air Act, Components listed as HAP	CAS 91-20-3, Naphthalene
Clean Water Act, Section 311, Table 116.4A	CAS 91-20-3, Naphthalene
Clean Water Act, Section 311, Table 117.3	CAS 91-20-3, Naphthalene
Clean Water Act, Section 307	CAS 91-20-3, Naphthalene
California Prop 65	This product contains a chemical known to the State of
	California to cause cancer. CAS 91-20-3, Naphthalene
DRC Conflict materials	Based upon information from our suppliers this product is
	"DRC Conflict Free" as defined by the SEC Conflict
	Minerals Final Rule.

#### 16. Other Information

While the information and recommendations in this publication are to the best of our knowledge, information and belief accurate at the date of publication, NOTHING HEREIN IS TO BE CONSTRUED AS A WARRANTY, EXPRESS OR OTHERWISE.

IN ALL CASES, IT IS THE RESPONSIBILITY OF THE USER TO DETERIMINE THE APPLICABILITY OF SUCH INFORMATION AND RECOMMENDATIONS AND THE SUITABILITY OF ANY PRODUCT FOR ITS OWN PARTICULAR PURPOSE.

THE PRODUCT MAY PRESENT HAZARDS AND SHOULD BE USED WITH CAUTION. WHILE CERTAIN HAZARDS ARE DESCRIBED IN THIS PUBLICATION, NO GUARANTEE IS MADE THAT THESE ARE THE ONLY HAZARDS THAT EXIST.

## Disclaimer:

The data set forth in this sheet is based on information provided by the suppliers of raw materials and chemicals used in the manufacture of the aforementioned product. Roadware Incorporated makes no warranty with respect to the accuracy of the information provided by their suppliers, and disclaims all liability of reliance thereof.